Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 80

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 80
---
as defined in the Certificate of Designations). We currently anticipate that we will retain future earnings to fund development and growth of our business, and we do not anticipate paying cash dividends on our common stock in the foreseeable future. The decision to pay dividends is at the discretion of our Board and depends upon our ability to obtain a waiver of the restriction on paying dividends contained in our credit facility, and on our financial condition, results of operations, capital requirements, and other factors that our Board deems relevant.

<div align='center'>43</div>

Capitalization The following table sets forth our capitalization as of September 30, 2024:

| ● | on an actual basis; |

| ● | on a pro forma basis to give effect to (i) the Vivus Event of Default and (ii) the Vivus Settlement. As a result of the Vivus Event of Default, the entire Promissory Note was reclassified as current debt. In addition, the Vivus Settlement adjustment gives effect to the proposed terms of the Foreclosure Notice and the corresponding transfer of Stendra inventory and API to Vivus, the application of $2.0 million in collateral as a reduction of debt and a $5.1 million loss on the Vivus Settlement (collectively, the “Vivus Adjustments”); and |

| ● | on a pro forma, as adjusted basis, after giving effect to (i) Vivus Adjustments, and (ii) the application of the net proceeds of this offering and after deducting the placement agent fees and estimated offering expenses payable by us (clauses (i) and (ii), the “Pro Forma Adjustments”). |

The information set forth in the following table should be read in conjunction with and is qualified in its entirety by “Use of Proceeds” above, as well as our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and the notes to those financial statements in this prospectus. See “The Offering” in this prospectus for information relating to the expected number of shares of our common stock to be outstanding after this offering. Our capitalization following the closing of this offering will be adjusted based on the actual public offering price and other terms of this offering determined at pricing.

| ​                                                                                                                                                                                                                                                                         | ​ 
 ​ | ​                        
 As of September 30, 2024 |            ​ | ​ | ​                     |            ​ | ​ 
 ​ | ​                          
 ​                          |            ​ |
|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------